Evidence map›Paper›PMID 34625544›Full record

ArticleNature communications2021

The regulatory landscape of the human HPF1- and ARH3-dependent ADP-ribosylome.

Ivo A Hendriks, Sara C Buch-Larsen, Evgeniia Prokhorova, Jonas D Elsborg, Alexandra K L F S Rebak, Kang Zhu, Dragana Ahel, Claudia Lukas, Ivan Ahel, Michael L Nielsen

Open access · goldAbstract read
In one paragraph

Article in Nature communications, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 64 papers.

0numbers the graph read from it
0cells of the map it votes in
64citing papers in PubMed
6.9field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

64 citing papers in PubMed, 98 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Article
  5. Review
  6. Article
  7. Article
  8. Review
  9. Article
  10. Article
  11. Article
  12. Article
  13. Review
  14. Article
  15. Article
  16. Unleashing viral mimicry: A combinatorial strategy to enhance the efficacy of PARP7 inhibitors.BioEssays : news and reviews in molecular, cellular and developmental biology · 2025
    Review
  17. Article
  18. Article
  19. Review
  20. Article

4 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 2 institutions in 2 countries.

Ivo A Hendriks *Proteomics Program, Novo Nordisk Foundation Center for Protein Research, Faculty of Health and Medical Sciences, University of Copenhagen, Blegdamsvej 3B, 2200, Copenhagen, Denmark.ORCID 0000-0002-1439-3701
Sara C Buch-Larsen *Proteomics Program, Novo Nordisk Foundation Center for Protein Research, Faculty of Health and Medical Sciences, University of Copenhagen, Blegdamsvej 3B, 2200, Copenhagen, Denmark.ORCID 0000-0001-6250-5467
Evgeniia ProkhorovaSir William Dunn School of Pathology, University of Oxford, Oxford, OX1 3RE, UK.ORCID 0000-0002-5467-5586
Jonas D ElsborgProteomics Program, Novo Nordisk Foundation Center for Protein Research, Faculty of Health and Medical Sciences, University of Copenhagen, Blegdamsvej 3B, 2200, Copenhagen, Denmark.ORCID 0000-0002-1506-4280
Alexandra K L F S RebakProteomics Program, Novo Nordisk Foundation Center for Protein Research, Faculty of Health and Medical Sciences, University of Copenhagen, Blegdamsvej 3B, 2200, Copenhagen, Denmark.
Kang ZhuSir William Dunn School of Pathology, University of Oxford, Oxford, OX1 3RE, UK.
Dragana AhelSir William Dunn School of Pathology, University of Oxford, Oxford, OX1 3RE, UK.
Claudia LukasProtein Signaling Program, Novo Nordisk Foundation Center for Protein Research, Faculty of Health and Medical Sciences, University of Copenhagen, Blegdamsvej 3B, 2200, Copenhagen, Denmark.ORCID 0000-0001-7169-6883
Ivan AhelSir William Dunn School of Pathology, University of Oxford, Oxford, OX1 3RE, UK.ORCID 0000-0002-9446-3756
Michael L NielsenProteomics Program, Novo Nordisk Foundation Center for Protein Research, Faculty of Health and Medical Sciences, University of Copenhagen, Blegdamsvej 3B, 2200, Copenhagen, Denmark. michael.lund.nielsen@cpr.ku.dk.ORCID 0000-0002-0067-9039
University of Copenhagen · DKUniversity of Oxford · GB

Funding

Biotechnology and Biological Sciences Research Council BB/R007195/1Cancer Research UK 16304Cancer Research UK 22284Cancer Research UK C35050/A22284Wellcome Trust 101794Wellcome Trust 210634Wellcome Trust 210634/Z/18/Z
6 · The paper itself

Abstract

Despite the involvement of Poly(ADP-ribose) polymerase-1 (PARP1) in many important biological pathways, the target residues of PARP1-mediated ADP-ribosylation remain ambiguous. To explicate the ADP-ribosylation regulome, we analyze human cells depleted for key regulators of PARP1 activity, histone PARylation factor 1 (HPF1) and ADP-ribosylhydrolase 3 (ARH3). Using quantitative proteomics, we characterize 1,596 ADP-ribosylation sites, displaying up to 1000-fold regulation across the investigated knockout cells. We find that HPF1 and ARH3 inversely and homogenously regulate the serine ADP-ribosylome on a proteome-wide scale with consistent adherence to lysine-serine-motifs, suggesting that targeting is independent of HPF1 and ARH3. Notably, we do not detect an HPF1-dependent target residue switch from serine to glutamate/aspartate under the investigated conditions. Our data support the notion that serine ADP-ribosylation mainly exists as mono-ADP-ribosylation in cells, and reveal a remarkable degree of histone co-modification with serine ADP-ribosylation and other post-translational modifications.

Indexed as

Adenosine DiphosphateADP-RibosylationCarrier ProteinsCell Line, TumorDNA DamageGene Knockout TechniquesGlycoside HydrolasesHistonesHumansNuclear ProteinsProtein Processing, Post-TranslationalProteomeProteomicsSerineAdenosine DiphosphateADPRS protein, humanCarrier ProteinsGlycoside HydrolasesHistonesHPF1 protein, humanNuclear ProteinsProteomeSerine

Identifiers

PMID34625544
PMCPMC8501107
OpenAlexW3202772783

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.